These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 32497550)

  • 41. Superior Pyrimidine Derivatives as Selective ABCG2 Inhibitors and Broad-Spectrum ABCB1, ABCC1, and ABCG2 Antagonists.
    Silbermann K; Li J; Namasivayam V; Baltes F; Bendas G; Stefan SM; Wiese M
    J Med Chem; 2020 Sep; 63(18):10412-10432. PubMed ID: 32787102
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2.
    Dai CL; Liang YJ; Wang YS; Tiwari AK; Yan YY; Wang F; Chen ZS; Tong XZ; Fu LW
    Cancer Lett; 2009 Jun; 279(1):74-83. PubMed ID: 19232821
    [TBL] [Abstract][Full Text] [Related]  

  • 43. ABCB1 limits brain exposure of the KRAS
    Loos NHC; Retmana IA; Li W; Martins MLF; Lebre MC; Sparidans RW; Beijnen JH; Schinkel AH
    Pharmacol Res; 2022 Apr; 178():106137. PubMed ID: 35192958
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effect of ceritinib (LDK378) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo.
    Hu J; Zhang X; Wang F; Wang X; Yang K; Xu M; To KK; Li Q; Fu L
    Oncotarget; 2015 Dec; 6(42):44643-59. PubMed ID: 26556876
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Overexpression of ABCB1 Transporter Confers Resistance to mTOR Inhibitor WYE-354 in Cancer Cells.
    Wang J; Yang DH; Yang Y; Wang JQ; Cai CY; Lei ZN; Teng QX; Wu ZX; Zhao L; Chen ZS
    Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32092870
    [TBL] [Abstract][Full Text] [Related]  

  • 46. P-glycoprotein (MDR1/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2) limit brain accumulation of the FLT3 inhibitor quizartinib in mice.
    Wang J; Gan C; Retmana IA; Sparidans RW; Li W; Lebre MC; Beijnen JH; Schinkel AH
    Int J Pharm; 2019 Feb; 556():172-180. PubMed ID: 30553002
    [TBL] [Abstract][Full Text] [Related]  

  • 47. ABCB1 attenuates brain exposure to the KRAS
    Rijmers J; Retmana IA; Bui V; Arguedas D; Lebre MC; Sparidans RW; Beijnen JH; Schinkel AH
    Biomed Pharmacother; 2024 Jun; 175():116720. PubMed ID: 38733773
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cyclin-dependent kinase inhibitors AZD5438 and R547 show potential for enhancing efficacy of daunorubicin-based anticancer therapy: Interaction with carbonyl-reducing enzymes and ABC transporters.
    Sorf A; Novotna E; Hofman J; Morell A; Staud F; Wsol V; Ceckova M
    Biochem Pharmacol; 2019 May; 163():290-298. PubMed ID: 30826329
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Semi-synthetic ocotillol analogues as selective ABCB1-mediated drug resistance reversal agents.
    Zhang YK; Zhang H; Zhang GN; Wang YJ; Kathawala RJ; Si R; Patel BA; Xu J; Chen ZS
    Oncotarget; 2015 Sep; 6(27):24277-90. PubMed ID: 26296969
    [TBL] [Abstract][Full Text] [Related]  

  • 50. P-glycoprotein Limits Ribociclib Brain Exposure and CYP3A4 Restricts Its Oral Bioavailability.
    Martínez-Chávez A; van Hoppe S; Rosing H; Lebre MC; Tibben M; Beijnen JH; Schinkel AH
    Mol Pharm; 2019 Sep; 16(9):3842-3852. PubMed ID: 31329454
    [TBL] [Abstract][Full Text] [Related]  

  • 51. P-glycoprotein (MDR1/ABCB1) restricts brain accumulation and cytochrome P450-3A (CYP3A) limits oral availability of the novel ALK/ROS1 inhibitor lorlatinib.
    Li W; Sparidans RW; Wang Y; Lebre MC; Wagenaar E; Beijnen JH; Schinkel AH
    Int J Cancer; 2018 Oct; 143(8):2029-2038. PubMed ID: 29744867
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The ABCB1 and ABCG2 efflux transporters limit brain disposition of the SYK inhibitors entospletinib and lanraplenib.
    Loos NHC; Sparidans RW; Heydari P; Bui V; Lebre MC; Beijnen JH; Schinkel AH
    Toxicol Appl Pharmacol; 2024 Apr; 485():116911. PubMed ID: 38527694
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Karanjin interferes with ABCB1, ABCC1, and ABCG2.
    Michaelis M; Rothweiler F; Nerreter T; Sharifi M; Ghafourian T; Cinatl J
    J Pharm Pharm Sci; 2014; 17(1):92-105. PubMed ID: 24735762
    [TBL] [Abstract][Full Text] [Related]  

  • 54. β-carotene reverses multidrug resistant cancer cells by selectively modulating human P-glycoprotein function.
    Teng YN; Sheu MJ; Hsieh YW; Wang RY; Chiang YC; Hung CC
    Phytomedicine; 2016 Mar; 23(3):316-23. PubMed ID: 26969385
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Rhinacanthin-C Mediated Herb-Drug Interactions with Drug Transporters and Phase I Drug-Metabolizing Enzymes.
    Dunkoksung W; Vardhanabhuti N; Siripong P; Jianmongkol S
    Drug Metab Dispos; 2019 Oct; 47(10):1040-1049. PubMed ID: 31399508
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Imidazo[1,2-
    Li H; Zhang SL; Jia YH; Li Q; Feng ZW; Zhang SD; Zheng W; Zhou YL; Li LL; Liu XC; Chen YQ; Peng H; You QD; Xu XL
    J Med Chem; 2023 Feb; 66(4):2804-2831. PubMed ID: 36780419
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Ceritinib Enhances the Efficacy of Substrate Chemotherapeutic Agent in Human ABCB1-Overexpressing Leukemia Cells In Vitro, In Vivo and Ex-Vivo.
    Yang L; Li M; Wang F; Zhen C; Luo M; Fang X; Zhang H; Zhang J; Li Q; Fu L
    Cell Physiol Biochem; 2018; 46(6):2487-2499. PubMed ID: 29742496
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Brain Exposure to the Macrocyclic ALK Inhibitor Zotizalkib is Restricted by ABCB1, and Its Plasma Disposition is Affected by Mouse Carboxylesterase 1c.
    Rijmers J; Sparidans RW; Acda M; Loos NHC; Epeslidou E; Bui V; Lebre MC; Tibben M; Beijnen JH; Schinkel AH
    Mol Pharm; 2024 Oct; 21(10):5159-5170. PubMed ID: 39312722
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Vatalanib sensitizes ABCB1 and ABCG2-overexpressing multidrug resistant colon cancer cells to chemotherapy under hypoxia.
    To KK; Poon DC; Wei Y; Wang F; Lin G; Fu LW
    Biochem Pharmacol; 2015 Sep; 97(1):27-37. PubMed ID: 26206183
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance.
    Shi Z; Peng XX; Kim IW; Shukla S; Si QS; Robey RW; Bates SE; Shen T; Ashby CR; Fu LW; Ambudkar SV; Chen ZS
    Cancer Res; 2007 Nov; 67(22):11012-20. PubMed ID: 18006847
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.